Kiniksa Pharmaceuticals International, PLC at Goldman Sachs Healthcare Conference Transcript
Okay, we'll continue with the next session. I'm Paul Choi, and I cover the Smithcat biotech sector here at the firm. It's our pleasure to have Kinixa here on stage with us for this session. To my immediate left is Rasmote, Head of Commercial, and then to my far left, John Paolini, Chief Medical Officer.
Maybe what we'll do is what we've done in earlier sessions, and I'll let either.
Ross or John, kick it off maybe with some high-level comments sort of on what are the company's strategic priorities for the remainder of the year and going into 2027, and then we can go into Q&A.
Great. Well, thank you very much, Paul. Really appreciate it, and thank you for the invite to be here today and to all of the Goldman team.
For hosting this event. It's a pleasure to be here. And thanks to everyone in the audience and those listening online. Before we go further, I will just mention that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
